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gories: Prospective, Retrospective, Modeling, Quality of
Life or Other. A total of 41 retrospective posters were
identiﬁed through this process, and all were evaluated
using a slightly modiﬁed ISPOR retrospective checklist (4
criteria were separated into components, yielding a total
of 14 points). This checklist helps evaluate the appropri-
ateness of the database, the study design, and the data
analysis procedures used. Posters were evaluated by three
reviewers to assess compliance with the criteria.
RESULTS: The median score was 7 points (out of 14 cri-
teria). The highest score was 11 points and the lowest
score was 5 points. More than three-fourths of the posters
did not conﬁrm the validity of their data (criterion 2),
inclusion/exclusion criteria (criterion 4b), sensitivity
analysis for controversial variables (criterion 5b), and 
the possibility of alternative explanations (criterion 10b).
More than half of the posters additionally failed to
acknowledge the study design limitations (criterion 3b),
describe the method and/or rationale for costing (crite-
rion 6), and control for confounding variables (criterion
7). CONCLUSION: Most of the posters in this conve-
nience sample ranked at the midpoint of the expanded
ISPOR checklist. Researchers should pay close attention
to the ISPOR checklist when preparing their poster pre-
sentations to assure consistently good research practices.
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OBJECTIVE: To evaluate whether the modeling posters
presented at the 2002 ISPOR Seventh Annual Interna-
tional Meeting met the standard of good research prac-
tice criteria established by British Medical Journal (BMJ)
and ISPOR. METHODS: Posters presented at the meeting
were collected onsite or from the ISPOR website. Of the
total 337 posters presented, 133 posters (39%) were eval-
uated. Of the 133 posters collected, 26 were classiﬁed 
as modeling. Nine (9) modeling posters were excluded
because they focused exclusively on the denominator or
numerator. The remaining 17 posters were evaluated in 3
major sections: a) study design (7 items for BMJ; 3 for
ISPOR); b) data validity (14 items for BMJ; 13 for
ISPOR); c) analysis and interpretation (14 items for BMJ;
23 for ISPOR). RESULTS: More than half of the posters
satisﬁed 75% or more of the ISPOR and BMJ criteria for
study design, and only 5 failed to satisfy at least 50% of
the study design criteria. Only six posters satisﬁed 50%
or more of the BMJ data validity criteria, and none of the
posters satisﬁed 50% or more of the ISPOR data validity
criteria. More than half of the posters satisﬁed 50% or
more of the BMJ and ISPOR criteria for analysis and
interpretation. Posters were slightly more likely to satisfy
the BMJ, rather than ISPOR criteria for data validity.
Overall, the 17 posters met 51% (18/35) of the BMJ cri-
teria and 46% (18/39) of the ISPOR criteria. CONCLU-
SIONS: The number of posters reviewed and the number
of evaluators limit this study. Reviewed posters revealed
satisfactory performance in the study design elements of
the ISPOR and BMJ guidelines, but could be improved 
in data validity and analysis. Generally, the posters per-
formed better when rated using the BMJ rather than the
ISPOR guideline.
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Pharmacoepidemiology is deﬁned as the application of
epidemiological reasoning methods and knowledge to the
study of the uses and effects (beneﬁcial and adverse) of
drugs in human populations. OBJECTIVES: The purpose
of this paper is to review the emerging role of pharma-
coepidemiology in outcomes research. METHODS: This
review has been based on a systematic literature search
using Medline (PubMed), including the abstracts of the
International Conference of Pharmacoepidemiolgy since
1990, and a review of core texts recommended by the
International Society for Pharmacoepidemiology (ISPE).
RESULTS: Three core functions were highlighted by
review of the literature. The major role was found to be
in the ﬁeld of pharmacovigilance and its function in phase
IV clinical trials or postmarketing surveillance. This was
reﬂected by the predominance of pharmacovigilance
abstracts accepted by the ISPE—90% (201/223) of
abstracts in 1990 and 72% (222/309) in 2001. Pharma-
covigilance, the process of identifying and responding to
drug safety issues during phase IV of drug development,
is a key requirement of many drug regulatory authorities,
including the FDA. Pharmacoepidemiology was also
found to play a role in drug utilisation review studies and
decision analytic modeling, although its use was found 
to be less substantial, constituting the balance of the
accepted abstracts. CONCLUSION: Although pharma-
coepidemiolgy has mainly been used in the ﬁeld of phar-
macovigilance, its use in decision analysis and drug
utilisation review was found to be on the increase.
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OBJECTIVES: Current data support the use of low mol-
ecular weight heparin (LMWH) in lieu of unfractionated
